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1. Introduction 
A number of molecular markers have recently been identified that may have prognostic 
value in breast cancer, and among the most notable of these are the estrogen receptor (ER) 
and the progesterone receptor (PR). ER/PR-positive breast cancer patients (60–80%) are 
hormone-responsive and therefore have a significantly better prognosis compared with 
ER/PR-negative patients (Clark and McGuire, 1983; Early Breast Cancer Trialists' 
Collaborative Group, 2005; Thorpe, 1988). However, approximately 50% of patients with 
advanced disease do not respond to endocrine therapy (Normanno et al., 2005). 
Another well-known prognostic marker is epidermal growth factor receptor-2 (ErbB2; also 
known as HER2), which is a member of the epidermal growth factor receptor (EGFR) 
family. In approximately 30% of human breast cancers, ErbB2 is present at levels 
significantly above those found in normal cells (Hynes and Stern, 1994; Stern, 2000; 
Yarden, 2001). Recent studies have indicated that ErbB2 plays important roles in 
malignant transformation and tumorigenesis (Hudziak et al., 1987; Slamon et al., 1987, 
1989). Therefore, breast cancer tumors that involve large amounts of ErbB2 protein are 
correlated with poor clinical outcomes (Menard et al., 2001). Herceptin (also known as 
Trastuzumab), a humanized monoclonal antibody against the extracellular domain of 
ErbB2, is used to treat patients expressing high levels of ErbB2. Although Herceptin 
significantly decreases the rates of breast cancer recurrence and mortality (Piccart-Gebhart 
et al., 2005; Slamon et al., 2001; Ward et al., 2009), almost 50% of patients with the ErbB2-
amplified tumors do not respond to this treatment and develop resistance to the drug 
(Slamon et al., 2006). 
Conversely, tumors with neither hormone receptor expression nor ErbB2 amplification 
are classified as triple-negative (TN) tumors (Sorlie et al., 2003). TN tumors are an 
aggressive subtype of breast cancer that account for approximately 15% of breast cancer 
cases. The TN tumor shows a higher histologic grade, and a worse prognosis compared 
with that of hormone receptor-positive or ErbB2-positive tumors (Dent et al., 2007; 
Liedtke et al., 2008). Therapeutically, despite being highly chemosensitive, their 
progression-free time is generally short (Dent et al., 2007; Liedtke et al., 2008), and TN 
tumors develop resistance to endocrine therapy and Herceptin, illustrating the urgent 
need for novel therapeutic strategies. Recently, new potential therapeutic targets for this 
type of breast cancer have been discovered, including poly-(ADP-ribose)-polymerase 1 
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(Bryant et al., 2005; Evers et al., 2008; Tutt et al., 2009), vascular endothelial growth factor 
receptor (Mendel et al., 2003), EGFR (Corkery et al., 2009; Pal and Mortimer, 2009), SRC 
tyrosine kinase (Conlin and Seidman, 2008; Finn, R.S., 2007), mammalian target of 
rapamycin (Saal et al., 2005), heat shock protein 90 (Caldas-Lopes et al., 2009), breast 
tumor kinase (BRK) and signal transducing adaptor protein-2 (STAP-2) (Mitchel et al., 
2000; Ikeda et al., 2009, 2010, 2011). 
STAP-2 is a recently identified adaptor protein, which contains pleckstrin homology (PH) 
and Src homology 2 (SH2)-like domains, as well as a signal transducer and activator of 
transcription 3 (STAT3)-binding motif in its C-terminal region (Minoguchi et al., 2003). 
Importantly, human STAP-2 was originally identified as BKS and is a substrate for BRK, a 
non-receptor protein tyrosine kinase (PTK) known alternatively as protein tyrosine kinase 
6 (PTK6) (Mitchell et al., 2000). BRK is highly expressed in human breast cancer cells 
(Barker et al., 1997). Recently, STAP-2, STAT3, and STAT5A/B have been identified as 
BRK substrates. However, the molecular mechanism by which the STAP-2-BRK-STAT3/5 
axis participates in the tumorigenesis in breast cancer remains poorly characterized. In 
this review, we focus on the STAP-2-BRK-STAT3/5 axis as a potential therapeutic target 
and/or prognostic marker and demonstrate a functional link between STAP-2 and 
BRK/STAT3/5-mediated transcriptional activation and cell growth in human breast 
cancer cells. 
2. STAP-2 
2.1 Structure and expression 
Human STAP-2 is the first identified substrate for the BRK non-receptor tyrosine kinase 
(Mitchell et al., 2000). We also cloned murine STAP-2 as a c-fms interacting protein 
(Minoguchi et al., 2003). PTKs play an important role in regulating cell growth, 
differentiation, and transformation. Activated receptor tyrosine kinases trans-
phosphorylate several tyrosines in their cytoplasmic domains, providing recognition sites 
for various adaptor and effector proteins in multiple signal transduction pathways. 
Adaptor proteins often function as inter- or intra-molecular bridges and thereby play an 
important role in the assembly of larger protein complexes or in the stabilization of 
certain conformational states. They also utilize their functional domains, such as SH2 and 
SH3 domains, to mediate interactions that link various proteins involved in signal 
transduction. 
STAP-1 was cloned as a c-kit-interacting protein and bears high sequence and structural 
similarity to its sister protein, STAP-2 (Masuhara et al., 2000) (Fig. 1A). Both STAP-1 and 
STAP-2 contain an N-terminal PH domain and a region weakly related to an SH2 domain 
(overall 33% amino acid identity). The N-terminal PH domains of the STAP proteins share 
36% amino acid identity and 58% similarity. In the absence of stimulation, over-expressed 
STAP-2 protein localizes throughout the cytoplasm and nucleus in A431 epidermoid 
carcinoma cells, but translocates to the plasma membrane following stimulation of EGFR. 
A mutant STAP-2 lacking the N-terminal PH domain (ΔPH) fails to localize at the plasma 
membrane, demonstrating that the PH domain of STAP-2 is necessary and sufficient for 
plasma membrane recruitment by EGFR stimulation. 
The central region of STAP-2 is distantly related to the SH2 domain. This region of STAP-2 
shares 40% sequence identity with that of STAP-1 and 29% sequence identity with the SH2 
domain of human phospholipase C-2. However, STAP-2 has a C-terminal proline-rich  
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Fig. 1. Schematic diagrams of the domain structures of the STAP-1 (A), STAP-2 (A, B), 
STAT3 (C), BRK and the STAP-2 PH-BRK fusion protein (D). 
region and a STAT3-binding motif, YXXQ, both of which are absent from STAP-1. Cytokine 
receptors commonly utilize a YXXQ motif in their cytoplasmic regions to recruit and 
activate STAT3 (Hirano et al., 2000). STAP-2 is expressed in a variety of tissues and cells 
such as lymphocytes, macrophages and hepatocytes (Minoguchi et al., 2003), and its 
abundant expression pattern (Fig. 2A) suggests that STAP-2 influences a variety of signaling 
or transcriptional molecules. STAP-1, however, shows a more restricted expression pattern, 
being located predominantly in hematopoietic cells (Masuhara et al., 2000). Notably, STAP-2 
is constitutively expressed in macrophages, and the 5’ region of the STAP-2 genomic 
sequence contains several potential binding sites for c-Rel, AP-1, p65/NF-B and STATs. In 
the murine myeloid leukemia cell line, M1, STAP-2 mRNA expression is strongly induced 
by LIF in parallel with its differentiation into macrophages. These expression patterns of 
STAP-2 support a paradigm whereby STAP-2 in macrophages mediates signals for acute-
phase responses after infection. Indeed, LPS- or IL-6-stimulated induction of acute phase 
protein genes was significantly decreased in STAP-2-deficient hepatocytes (Minoguchi et al., 
2003). 
www.intechopen.com
 
Breast Cancer – Carcinogenesis, Cell Growth and Signalling Pathways 
 
596 
C
A
He
La
He
p3
B
Ak
ata
DG
75
29
3T
BJ
AB
Da
ud
i
Ra
mo
s
SK
W
6.C
l4 IB
4
Ra
ji
HL
60
K5
62
Ju
rka
t
MA
LT
4
U9
37
TH
P1
SW
48
0
Hu
t78
Ca
co
-2
HT
29
HC
T1
16
T4
7D
MC
F7
MD
A-
MB
23
1
TS
U-
Pr
DU
14
5
PC
3
Embronic kidney
Cervical carcinoma
Hepatoma
B cell T cell Colon 
cancer
Breast
cancer
Prostate 
cancerPromyeloblast
Lymphoblast
0
250
500
1000
750
Re
lat
ive
 S
TA
P-
2 m
RN
A 
ex
pre
ss
ion STAP-2
0
50
100
200
150
Re
lat
ive
 B
RK
 m
RN
A 
ex
pre
ss
ion
BRK
He
La
He
p3
B
Ak
ata
DG
75
29
3T
BJ
AB
Da
ud
i
Ra
mo
s
SK
W
6.C
l4 IB
4
Ra
ji
HL
60
K5
62
Ju
rka
t
MA
LT
4
U9
37
TH
P1
SW
48
0
Hu
t78
Ca
co
-2
HT
29
HC
T1
16
T4
7D
MC
F7
MD
A-
MB
23
1
TS
U-
Pr
DU
14
5
PC
3
Re
lat
ive
 S
TA
P-
2 m
RN
A 
ex
pre
ss
ion
Re
lat
ive
 B
RK
 m
RN
A 
ex
pre
ss
ion
 
Fig. 2. Expression profile of STAP-2 and BRK. Expression of STAP-2 and BRK in a variety of 
human cell lines (A, B). Total RNA samples isolated from these cells were also subjected to 
quantitative real-time PCR analysis using STAP-2 and BRK primers. Data represent the 
levels of these mRNA normalized to that of an ACTIN internal control and are expressed 
relative to the value of 293T samples. Shown is a representative experiment, which was 
repeated at least three times with similar results. 
2.2 Interacting proteins 
Recently, many STAP-2 binding partners have been identified. As summarized in Table 1, 
STAP-2 interacts with, and modulates the function of, several signaling molecules including 
STAT3/5- (Minoguchi et al., 2003; Sekine et al., 2005), FcRI- (Yamamoto et al., 2003), M-
CSFR/c-FMS- (Ikeda et al., 2007) and Toll-like receptor-mediated signals (Sekine et al., 
2006). STAP-2 interacts with STAT3 through the C-terminal YXXQ motif and enhances 
STAT3 transcriptional activity. STAP-2 also interacts with STAT5 through its PH and SH2-
like domains. It is noteworthy that thymocytes and peripheral T cells from STAP-2-deficient 
mice show enhanced IL-2- or TCR-dependent cell growth (Sekine et al., 2005). STAP-2 
positively regulates LPS/TLR4-mediated signals in macrophages. STAP-2, particularly its 
SH2-like domain, binds to both MyD88 and IKK-/, but not to TRAF6 or IRAK1, and 
 
B
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forms a functional complex composed of MyD88-STAP-2-IKK-/. These interactions 
augment MyD88- and/or IKK/-dependent signals, leading to enhancement of NF-B 
activity (Sekine et al., 2006). 
 
Sekine et al., 2009Not determinedRac1
Sekine et al., 2009SH2-like, C-terminalVav1
Sekine et al., 2007PH, SH2-likeCbl
Sekine et al., 2007SH2-likeFAK
Ikeda et al., 2008PH, SH2-likeTRAF3
Ikeda et al., 2008Not determinedTRAF1
Ikeda et al., 2008PH, SH2-likeLMP1
Sekine et al., 2006SH2-likeIKK/
Sekine et al., 2006SH2-likeMyD88
Yamamoto et al., 2003SH2-like, C-terminalPLC1/2
Ikeda et al., 2007PH, (SH2-like)c-Fms
Sekine et al., 2005PH, SH2-likeSTAT5A/B
Ikeda et al., 2010; Minoguchi et al., 2003YXXQ motif, (SH2-like)STAT3
Ikeda et al., 2009, 2010, 2011; Mitchel et al., 2000 PH, (SH2-like)BRK
ReferencesDomain or regionInteracting protein
 
Table 1. STAP-2 interacting proteins. 
M-CSFR/c-FMS directly interacts with the PH domain of STAP-2 independently following 
M-CSF-stimulation (Ikeda et al., 2007). STAP-2 regulates M-CSF-induced tyrosine 
phosphorylation of M-CSFR/c-FMS as well as the activation of Akt and extracellular signal 
regulated kinase. In addition, over-expression of STAP-2 results in the impairment of 
migration in response to M-CSF and of the wound-healing process in macrophages. This 
demonstrates that STAP-2 directly binds to M-CSFR/c-FMS and interferes with PI3K 
signaling, leading to macrophage motility. In T cells, STAP-2 enhances Cbl-dependent 
degradation of FAK and downregulates integrin/FAK-mediated cell adhesion to fibronectin 
(Sekine et al., 2007). Furthermore, STAP-2 constitutively interacts with, and enhances the 
tyrosine phosphorylation of, a GDP/GTP exchange factor, Vav1, and also binds to a small 
GTPase, Rac1 (Sekine et al., 2009). These interactions control chemokine-induced chemotaxis 
of T cells. 
STAP-2 also interacts with Epstein-Barr virus (EBV)-derived latent membrane protein 1 
(LMP1) and negatively regulates LMP1-induced NF-B activation (Ikeda et al., 2008). EBV is 
linked to the development of multiple malignancies, including post-transplant lymphoma, 
Hodgkin disease, and nasopharyngeal carcinoma (Thorley-Lawson, 2001). EBV-LMP1 is 
expressed in many EBV-associated tumor cells and is responsible for most of their altered 
cellular growth properties (Brinkmann and Schulz, 2006). STAP-2 associates with LMP1 
through the PH and SH-2-like domains, and this interaction occurs physiologically in EBV-
positive human B cells. STAP-2 regulates LMP1-mediated NF-B signaling through direct or 
indirect interactions with TRAF3 and TRADD. Importantly, STAP-2 mRNA is induced by 
expression of LMP1 in human B cells, and transient expression of STAP-2 in EBV-positive 
human B cells decreases cell growth. These data suggest that STAP-2 responds to EBV 
infection and acts as an endogenous negative regulator of EBV-LMP1-mediated signaling 
through TRAF3 and TRADD. 
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3. BRK 
3.1 Structure and expression 
BRK was originally isolated from a metastatic breast carcinoma (Mitchell et al., 1994). An 
identical protein was independently cloned as a highly-expressed protein tyrosine kinase, 
PTK6, from human melanocytes (Lee et al., 1993). In addition, Ptk6 (previously termed 
Sik), a cDNA for the mouse ortholog that has 80% amino acid identity to BRK/PTK6, was 
also cloned from mouse intestinal crypt cells (Siyanova et al., 1994). BRK displays 
approximately 56% homology to the kinase domain of c-Src and a similar domain 
arrangement (Serfas and Tyner, 2003). BRK is a 451 amino acid protein that contains an 
SH3 domain, an SH2 domain and a tyrosine kinase catalytic domain, but lacks an N-
terminal myristoylation site for membrane targeting (Serfas and Tyner, 2003). BRK is 
expressed in many malignancies, such as colon and prostate tumors and metastatic 
melanomas (Derry et al., 2003; Easty et al., 1997; Llor et al., 1999; Schmandt et al., 2006). 
BRK expression is also detected in a large proportion of human mammary gland tumors, 
but is not expressed in normal mammary gland (Barker et al., 1997). In normal tissues, 
BRK expression is developmentally regulated and restricted to differentiating epithelial 
cells in a range of tissues including small intestine and colon (Vasioukhin et al., 1995; 
Haegebarth et al., 2005, 2006) (Fig. 2B). 
3.2 Substrates, interacting proteins and activation 
Several BRK-interacting proteins or substrates have been identified (Table 2). BRK 
substrates include RNA-binding proteins (Sam68 (Coyle et al., 2003; Derry et al., 2000; 
Lukong et al., 2005), SLM-1/2 (Haegebarth et al., 2004), and the polypyrimidine tract-
binding protein-associated splicing factor (PSF) (Lukong et al., 2009)), transcription 
factors (STAT3 (Liu et al., 2006) and STAT5A/B (Weaver and Silva, 2007)), adaptor 
molecules (STAP-2) (Mitchell et al., 2000), and a variety of signaling molecules (paxillin 
(Chen et al., 2004), p190RhoGAP (Shen et al., 2008), kinesin-associated protein 3A 
(KAP3A) (Lukong and Richard, 2008), Akt (Zhang et al., 2005), -catenin (Palka-Hamblin 
et al., 2010), and ARAP1 (Arf-GAP, Rho-GAP, ankyrin repeat and PH domain-containing 
protein 1; also known as centaurin δ-2) (Kang et al., 2010)). Although BRK expression is 
known to induce tyrosine phosphorylation in some of these, similar actions in others have 
yet to be confirmed. 
Sam68 is the most extensively studied BRK substrate. BRK expression suppressed cell 
proliferation through EGFR-mediated phosphorylation of Sam68 in a human breast cancer 
cell line (Coyle et al., 2003; Derry et al., 2000; Lukong et al., 2005). Similarly, BRK 
phosphorylates the Sam68-like mammalian proteins, SLM-1 and SLM-2, and negatively 
regulates their RNA-binding functions (Haegebarth et al., 2004). Downstream of EGFR, PSF 
is a BRK substrate, and this tyrosine phosphorylation of PSF induces cytoplasmic 
relocalization, impairment of its binding to polypyrimidine RNA, and cell cycle arrest 
(Lukong et al., 2009). Furthermore, BRK expression promotes cell migration and tumor 
invasion by phosphorylating the focal adhesion protein, paxillin, followed by activation of 
the small GTPase, Rac1, via the function of CrkII (Chen et al., 2004). BRK also 
phosphorylates p190RhoGAP-A (regulating the small GTPases, RhoA and Ras, and 
promoting breast malignancy) (Shen et al., 2008); a kinesin-2 subunit, KAP3A (promoting 
cell migration) (Lukong and Richard, 2008); and Akt (regulating basal Akt activity in normal 
cells) (Zhang et al., 2005). 
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Qiu and Miller, 2002Y13, Y61, Y66, Y114, Y342, Y351Regulation of kinase activityBRK
Kang et al., 2010Y231Regulation of EGFR internalization ARAP1/centaurin-2
Palka-Hamblin et al., 2010Y64, Y142, Y331, Y333Cell growthbeta-catenin
Zhang et al., 2005Not determinedIntestinal epithelial cell differentiationAkt
Lukong and Richard, 2008C-terminusMigrationKAP3A
Shen et al., 2008Y1109Migrationp190RhoGAP
Chen et al., 2004Y31, Y118MigrationPaxillin
Ikeda et al., 2009; Mitchel et al., 2000 Y250Cell growthSTAP-2/BKS
Weaver and Silva, 2007Y694/Y699Cell cycleSTAT5A/B
Liu et al., 2006Y705Cell cycleSTAT3
Lukong et al., 2009C-terminusCell cyclePSF
Haegebarth et al., 2004Not determinedNot validatedSLM-1/SLM-2
Coyle et al., 2003; Derry et al., 2000; Lukong et al., 2005Y345, Y434, Y440Cell cycleSAM68
ReferencesPhosphorylation siteFunctionSubstrate
 
Table 2. BRK substrates. 
Mice deficient in the BRK murine ortholog, Sik, show increased cell proliferation, decreased 
apoptosis, and increased levels of activated Akt in the small intestine (Haegebarth et al., 2006), 
suggesting a role for BRK in differentiation of epithelial cells of the small intestine. This is 
further implied by the evidence that BRK directly phosphorylates and inhibits -catenin, 
interrupting T-cell factor-mediated transcription in the intestine, and indicating that BRK may 
be a negative regulator of the Wnt-signaling pathway (Palka-Hamblin et al., 2010). 
BRK may contribute to tumorigenesis by modulating EGF/EGFR signaling. It 
phosphorylates ARAP1, which results sequentially in inhibition of EGFR internalization, 
increased duration of EGF/EGFR signaling, and increased oncogenic capacity (Kang et al., 
2010). Importantly, over-expression of BRK sensitizes human mammary epithelial cells to 
EGF and/or heregulin stimuli, and increases anchorage-independent growth (Kamalati et 
al., 1996, 2000), while down-regulation of BRK also influences EGF- and heregulin-induced 
cell proliferation. These observations suggest that BRK is involved in signaling induced by 
members of the EGFR family (Ostrander et al., 2007). Notably, BRK interacts with additional 
ErbB family members (ErbB2, ErbB3, and ErbB4) as well as EGFR (ErbB1) (Kamalati et al., 
1996; Aubele et al., 2007; Xiang et al., 2008). BRK is co-amplified with ErbB2 to promote 
proliferation and confer resistance to lapatinib, an ErbB2 kinase inhibitor in breast cancer 
(Xiang et al., 2008), suggesting that BRK is a potential target in ErbB2-positive breast cancer. 
As mentioned above, BRK kinase activity is promoted by ligands for the ErbB receptor, such 
as EGF and heregulin. However, it is also activated by the expression of ErbB2 even in the 
absence of ligands, and by other stimuli such as IGF-1 (Qiu et al., 2005), calcium and 
ionomycin (Vasioukhin and Tyner, 1997; Wang et al., 2005), fetal bovine serum (Zhang et al., 
2005), and osteopontin (Chakraborty et al., 2008). BRK activation occurs under the 
conditions already described, but also during keratinocyte differentiation, together with 
upregulation of expression (Wang et al., 2005). 
The mechanism of regulation of BRK kinase activity is similar to SRC family kinases, with 
some notable differences. Structural studies reveal that BRK is autophosphorylated at Tyr-
13, 61, 66, 114, 351 and 342 (Qiu and Miller, 2002). Tyr-342 (Y342 in BRK and Y416 in SRC) 
resides within the kinase activation loop, and phosphorylation of this residue increases 
kinase activity of wild-type (WT) BRK. However, mutation of Tyr-342 to alanine (Y342A) 
blocks activation of BRK (Qiu and Miller, 2002). In addition, mutation of the C-terminal 
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residue Tyr-447 (Y447 in BRK and Y527 in SRC) to Phe (Y447F) results in a constitutively 
active kinase (Kamalati et al., 1996). Trp-184 (W184 in BRK and W260 in SRC) lies within the 
SH2-kinase linker region and, in contrast to SRC family enzymes, has been shown to interact 
intramolecularly with residues in the BRK kinase domain. The conserved Trp184 to Ala 
(W184A) mutation completely inhibits kinase activity (Kim and Lee, 2005), as does the 
substitution of Lys-219 (K219 in BRK and K295 in SRC) with Met (K219M), which destroys 
the putative ATP binding site of BRK (Kamalati et al., 1996). 
Unlike SRC family kinases, BRK lacks myristoylation signals for membrane targeting, 
allowing it some freedom in its subcellular localization and broadening its range of 
substrates and interacting proteins. Several studies demonstrate that the function of BRK 
varies between cell types and may be dependent on expression levels, kinase activity, 
interaction with substrates or other binding proteins and, significantly, on intracellular 
localization. Indeed, oncogenic functions of BRK are enhanced by targeting it to the plasma 
membrane but are abolished if it is modified to remain in the nucleus (Ie Kim and Lee, 
2009). BRK expression is detected in both the cytoplasm and nucleus in the normal intestine, 
skin and oral epithelium, and in breast and colon tumors (Brauer and Tyner, 2010). In 
normal differentiated prostate epithelium and in well-differentiated prostate tumors, it is 
detected in the nucleus, but is absent from the nuclei of poorly-differentiated tumors, which 
may implicate it in differentiation of the prostate  (Derry et al., 2003). At the present time, it 
is not clear how intracellular localization of BRK is regulated. Therefore, further studies are 
required to confirm the significance of BRK subcellular localization. Indeed, BRK does not 
contain any nuclear localization or export signal, suggesting that interaction with substrates 
such as STAP-2 or other interacting proteins may be important in regulating its distribution. 
4. Signal transducer and activator of transcription (STAT) 3/5 
The signal transducer and activator of transcription (STAT) family is known to mediate cell 
proliferation, differentiation and survival in immune responses, hematopoiesis, 
neurogenesis and many other biological processes (Darnell et al., 1994; Ihle, 1996; O'Shea, 
1997). Seven different STAT genes have currently been identified in mammals. The encoded 
proteins vary in length between 750–850 amino acid residues and share 20–50% amino acid 
sequence identity. As shown in Fig. 1, notable features of STAT proteins are the STAT 
family DNA binding domain, an SH2 domain and a major tyrosine phosphorylation site at 
Y705 (STAT3). In general, STAT proteins bind as dimers to DNA target sites with a nine-
base-pair (bp) consensus sequence, TTCCGGGAA, and binding constants in the nanomolar 
range. In unstimulated cells, STATs are present as monomers in the cytoplasm. STATs are 
activated by phosphorylation at tyrosine residues, which leads to the formation of dimers 
via reciprocal interactions between the SH2 domain of one monomer and the 
phosphorylated tyrosine of the other. Dimers then translocate to the nucleus where they 
recognize specific DNA-binding sites and induce target gene transcription. Tyrosine 
phosphorylation of STATs (Y705 in STAT3, and Y694/Y699 in STAT5A/B, respectively) is 
normally a transient and tightly regulated process. However, in tumor cells, constitutive 
activation of STATs is linked to persistent activity of tyrosine kinases, including Janus 
kinases, Src, EGFR, Bcr-Abl, and many others. These kinases might be activated by cytokines 
or by structural alterations. For instance, EGFR over-expression and activation may underlie 
STAT activation in breast, lung and head and neck cancer (Zhang et al., 2004). Constitutive 
activation or dysregulated expression of STATs is detected in primary tumors and cancer 
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cell lines, including leukemia, multiple myeloma, lymphomas, melanoma and cancers of the 
breast, skin, lung, ovaries, pancreas, prostate, kidney, thyroid, and head and neck 
(Desrivieres et al., 2006). Persistent signaling of specific STATs, particularly STAT3 and 
STAT5, has been demonstrated to directly contribute to oncogenesis by stimulating cell 
proliferation and preventing apoptosis (Bowman et al., 2000). 
5. Interactions of STAP-2 with BRK and STAT3/5 
5.1 BRK, STAP-2 and STAT3/5 
STAP-2 is the first BRK interacting protein identified and shown to be phosphorylated. 
STAT3 and STAT5, which play crucial roles in cell proliferation and differentiation, are also 
believed to be activated by BRK (Liu et al., 2006; Weaver and Silva, 2007). Our previous 
studies demonstrate that STAP-2 interacts with and influences several signaling molecules, 
including STAT3 and STAT5. Furthermore, both STATs play fundamental roles in the 
normal growth and development of the mammary gland (Hennighausen et al., 1997), and 
are often over-expressed or constitutively-activated in breast cancer tumors (Bowman et al., 
2000). It is therefore of key importance to clarify the interactions between BRK, STAP-2, and 
STAT3/5. 
5.2 STAT3/5 activation by BRK and STAP-2 
We attempted to elucidate the roles of STAP-2 in BRK-mediated transcriptional activation of 
STAT3/5 in breast cancer cells. Transient transfection experiments using expression of 
luciferase (Luc) reporter genes driven by STAT3 (STAT3-Luc) and STAT5 (STAT5-Luc) 
showed that STAP-2 enhances BRK-mediated activation of STAT3 and STAT5. We showed 
that co-expression of STAP-2 and BRK increases BRK-mediated STAT3/5 activation 
compared with BRK expression alone, and small-interfering RNA or short-hairpin RNA-
mediated reduction of endogenous STAP-2 expression strongly decreases BRK-mediated 
STAT3/5 activation in T47D human breast cancer cells. To further clarify the molecular 
mechanisms underlying BRK/STAP-2-mediated STAT3/5 activation in breast cancer cells, 
we tested the effect of STAP-2 on BRK-mediated phosphorylation of STAT3/5, which is an 
important step for transcriptional activation. Phosphorylation of STAT3/5 is markedly 
enhanced in MCF7 human breast cancer cells overexpressing STAP-2. In addition, 
constitutive phosphorylation of STAT3/5 in control T47D cells is markedly reduced in 
STAP-2 knockdown cell clones. These results indicate that STAP-2 plays important roles in 
BRK-mediated tyrosine phosphorylation of STAT3/5 in breast cancer cells. 
5.3 Molecular interactions among STAP-2, STAT3, STAT5 and BRK 
We previously reported that STAP-2 binds to several functional molecules. For example, the 
SH2 domain of STAP-2 interacts with MyD88 and IKKs (Sekine et al., 2006), and the PH and 
SH2 domains of STAP-2 mediate its association with STAT5 (Sekine et al., 2005), LMP1 and 
TRAF3 (Ikeda et al., 2008). To assess the functional relationships among BRK, STAP-2 and 
STAT3/5, we determined the domains of STAP-2 responsible for BRK-mediated STAT3/5 
activation. The BRK-mediated STAT3/5-Luc activity is significantly and dose-dependently 
enhanced by expression of STAP-2 WT and, to a slightly lesser degree, by expression of the 
mutant STAP-2 SH2 and STAP-2 C genes, which lack the SH2 domain and the C-terminal 
domain, respectively. Importantly, however, STAP-2PH (lacking the PH domain) does not 
elevate STAT3/5-Luc activity mediated by BRK. Similarly, enhanced phosphorylation of 
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STAT3/5 by BRK is observed in the presence of a construct encoding just the STAP-2 PH 
domain (STAP-2 PH). These findings indicate that the PH domain of STAP-2 plays an 
essential role in the BRK-mediated STAT3/5 activation. However, BRK-mediated STAT3/5 
phosphorylation is incomplete in the presence of the STAP-2 PH domain compared to that 
induced by STAP-2 WT, indicating that other domains of STAP-2 may be required for full 
BRK-mediated STAT3/5 phosphorylation. 
5.4 BRK kinase activity and intracellular localization 
Aside from differences in phosphorylation profiles, further differences between STAP-2 WT 
and STAP-2 PH were confirmed with confocal microscopy experiments. STAP-2 WT is 
distributed throughout the cytoplasm and nucleus, but STAP-2 PH is located mainly in the 
cytoplasm. Interestingly, BRK distribution is largely consistent with that of STAP-2, being 
localized in the nucleus only in the presence of STAP-2 WT, and localizing entirely in the 
cytoplasm when the PH domain of STAP-2 is disrupted (i.e. in the presence of STAP-2 PH).  
From this, we can conclude that STAP-2, via its PH domain, affects BRK distribution, 
probably because of its effects on the activation state of BRK. To clarify the effect of the 
STAP-2 PH domain on BRK activation, we used a STAP-2 PH-BRK fusion protein (PH-
BRK), in which BRK is fused to the N terminus of STAP-2 PH. PH-BRK shows robust kinase 
activity compared with BRK WT and induces marked activation and tyrosine 
phosphorylation of STAT3 in breast cancer cells. Moreover, PH-BRK is mainly localized in 
the nucleus, although BRK is localized throughout the cytoplasm and nucleus. Therefore, 
the STAP-2 PH domain controls the kinase activity and localization of BRK and thus 
regulates BRK-mediated STAT3 activation. Similarly, PH-BRK also activates STAT5 (data 
not shown). 
5.5 Cell growth 
STAP-2 knockdown T47D clones grow more slowly than control T47D cells. Reducing the 
expression of BRK, STAT3, STAT5b, or STAP-2 expression in T47D cells using siRNA causes 
a significant decrease in cell growth, indicating that these proteins play important roles in 
T47D cell growth. It is noteworthy that growth is decreased to similar extents in these four 
T47D cell types. This may suggest that BRK-induced cell growth in T47D cells is largely 
dependent on STAT3/5 and STAP-2. Notably, the expression of several genes in the 
STAT3/5-mediated signaling pathway, including SOCS3, C/EBP, cyclin D1, and c-Myc, is 
also reduced by STAP-2 knockdown in T47D cells. Taken together, BRK⁄STAT3/5-mediated 
proliferation is a major mechanism for breast cancer cell growth, and STAP-2 plays essential 
roles in this process. 
6. Conclusion 
Activation of STAT3/5 by BRK is a critical event during the process of BRK-mediated 
tumorigenesis in breast cancer cells. Our manipulation of STAP-2 expression revealed 
essential roles of STAP-2 in this process through complex interactions between BRK, STAP-2 
and STAT3/5. In particular, experiments using deletion mutants indicated that the PH 
domain of STAP-2 is involved in multiple processes including binding between BRK and 
STAP-2, activation and phosphorylation of STAT3/5, and activation of BRK. These findings 
suggest a model for how STAP-2 cooperates with BRK to enhance breast cancer growth. Our 
proposed mechanisms are now illustrated in Fig. 3. Taken together, STAP-2 plays crucial  
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Fig. 3. Schematic showing the proposed function of STAP-2 in BRK-mediated STAT 
signaling. STAT activation occurs as shown via growth factor receptor signaling (EGFR), or 
nonreceptor tyrosine kinase signaling (BRK). BRK is not required when STATs bind directly 
to EGFR for activation (upper left), but BRK enhances activation of STATs phosphorylated 
by EGFR-activated BRK (upper right). In this pathway, STAP-2 can form complex with BRK 
and STAT, leading to activation of both BRK and STAT. Once activated, STATs dimerize 
and translocate to the nucleus where they activate the transcription of genes involved in 
proliferation, survival, and differentiation. 
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roles in both the BRK/STAT3 and BRK/STAT5 axes, which are major events for BRK-
induced breast cancers. Our findings regarding BRK/STAP-2 interactions will therefore be 
helpful in developing breast cancer treatments. Furthermore, the synergistic effects of BRK 
and STAP-2 on STAT3/5 activation suggest that evaluating the expression of BRK together 
with STAP-2 may provide more useful prognostic scores for the outcomes of breast 
carcinomas than by measuring BRK expression alone. 
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